Medical Physics Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain.
Radiation Oncology Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain.
PLoS One. 2019 Aug 16;14(8):e0221262. doi: 10.1371/journal.pone.0221262. eCollection 2019.
mARC (modulated arc) is the arc therapy technique provided by Siemens. The present study analyses the dose distributions and treatment times corresponding to preoperative rectal cancer mARC treatments. The results are compared to those corresponding to 3D-CRT plans.
The plans of 30 patients, each having one mARC and one 3D-CRT plan, were evaluated. Every plan was calculated on a sequential two-phase treatment scheme with prescription doses of 45 Gy in the initial phase and 5.4 Gy in the boost phase. Dosimetric parameters and mean DVHs corresponding to the PTVs and OARs were assessed for both techniques.
All mARC plans were considered valid for treatment and yielded a highly significant improvement in the CI over 3D-CRT plans (p <0.001). They also showed statistically significant advantage on the parameters D98%, D95% and D2% of the high dose PTV. Regarding the OARs, mARC plans showed reductions in the mean dose of 3.5 Gy in the bladder and greater than 4 Gy in the femoral heads. Considering the small bowel, the mARC plans resulted in a 2.7 Gy mean reduction in the mean dose and lower irradiated volumes over the entire dose range.
Arc therapy plans with the mARC technique for preoperative rectal cancer treatment in a sequential two-phase treatment scheme provide important advantages in the PTVs and OARs. mARC plans show superior protection of the femoral heads, bladder and small bowel, similar to the results found with other more widespread arc therapy techniques.
mARC(调制弧)是西门子提供的弧形治疗技术。本研究分析了术前直肠癌 mARC 治疗的剂量分布和治疗时间。将结果与 3D-CRT 计划的结果进行比较。
评估了 30 名患者的计划,每位患者有一个 mARC 和一个 3D-CRT 计划。每个计划都根据序贯两阶段治疗方案进行计算,初始阶段的处方剂量为 45Gy,增强阶段为 5.4Gy。对两种技术的 PTV 和 OAR 的剂量学参数和平均 DVH 进行评估。
所有 mARC 计划均被认为可用于治疗,与 3D-CRT 计划相比,CI 有显著提高(p<0.001)。它们在高剂量 PTV 的 D98%、D95%和 D2%等参数上也具有统计学上的优势。对于 OAR,mARC 计划可使膀胱的平均剂量降低 3.5Gy,股骨头的平均剂量降低超过 4Gy。对于小肠,mARC 计划可使平均剂量降低 2.7Gy,整个剂量范围内的照射体积降低。
在序贯两阶段治疗方案中,用于术前直肠癌治疗的 mARC 技术的弧形治疗计划可在 PTV 和 OAR 中提供重要优势。mARC 计划对头骨、膀胱和小肠有更好的保护作用,与其他更广泛使用的弧形治疗技术的结果相似。